Literature DB >> 28775096

Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis.

Brijendra Singh1, Rajesh K Kasam1,2, Vishwaraj Sontake1,2, Thomas A Wynn3, Satish K Madala4.   

Abstract

IL-4 and IL-13 are major T-helper cell (Th) 2 cytokines implicated in the pathogenesis of several lung diseases, including pulmonary fibrosis. In this study, using a novel repetitive intradermal bleomycin model in which mice develop extensive lung fibrosis and a progressive decline in lung function compared with saline-treated control mice, we investigated profibrotic functions of Th2 cytokines. To determine the role of IL-13 signaling in the pathogenesis of bleomycin-induced pulmonary fibrosis, wild-type, IL-13, and IL-4Rα-deficient mice were treated with bleomycin, and lungs were assessed for changes in lung function and pulmonary fibrosis. Histological staining and lung function measurements demonstrated that collagen deposition and lung function decline were attenuated in mice deficient in either IL-13 or IL-4Rα-driven signaling compared with wild-type mice treated with bleomycin. Furthermore, our results demonstrated that IL-13 and IL-4Rα-driven signaling are involved in excessive migration of macrophages and fibroblasts. Notably, our findings demonstrated that IL-13-driven migration involves increased phospho-focal adhesion kinase signaling and F-actin polymerization. Importantly, in vivo findings demonstrated that IL-13 augments matrix metalloproteinase (MMP)-2 and MMP9 activity that has also been shown to increase migration and invasiveness of fibroblasts in the lungs during bleomycin-induced pulmonary fibrosis. Together, our findings demonstrate a pathogenic role for Th2-cytokine signaling that includes excessive migration and protease activity involved in severe fibrotic lung disease.

Entities:  

Keywords:  T-helper cell 2 cytokines; interleukin-13; matrix metalloproteinase activity; migration

Mesh:

Substances:

Year:  2017        PMID: 28775096      PMCID: PMC5792179          DOI: 10.1152/ajplung.00184.2017

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  48 in total

Review 1.  Mechanisms of pulmonary fibrosis.

Authors:  Victor J Thannickal; Galen B Toews; Eric S White; Joseph P Lynch; Fernando J Martinez
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

2.  Unique and Redundant Functions of p70 Ribosomal S6 Kinase Isoforms Regulate Mesenchymal Cell Proliferation and Migration in Pulmonary Fibrosis.

Authors:  Satish K Madala; Vishwaraj Sontake; Ramakrishna Edukulla; Cynthia R Davidson; Stephanie Schmidt; William D Hardie
Journal:  Am J Respir Cell Mol Biol       Date:  2016-12       Impact factor: 6.914

Review 3.  Metalloproteinases in idiopathic pulmonary fibrosis.

Authors:  R C A Dancer; A M Wood; D R Thickett
Journal:  Eur Respir J       Date:  2011-06-23       Impact factor: 16.671

4.  IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis.

Authors:  J F Urban; N Noben-Trauth; D D Donaldson; K B Madden; S C Morris; M Collins; F D Finkelman
Journal:  Immunity       Date:  1998-02       Impact factor: 31.745

5.  Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung.

Authors:  A Hancock; L Armstrong; R Gama; A Millar
Journal:  Am J Respir Cell Mol Biol       Date:  1998-01       Impact factor: 6.914

Review 6.  Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis.

Authors:  Claudia Jakubzick; Steven L Kunkel; Raj K Puri; Cory M Hogaboam
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

7.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

8.  Endogenously expressed IL-13Rα2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts.

Authors:  Sanjay Chandriani; Daryle J DePianto; Elsa N N'Diaye; Alexander R Abbas; Janet Jackman; Jack Bevers; Vladimir Ramirez-Carrozzi; Rajita Pappu; Steven E Kauder; Karen Toy; Connie Ha; Zora Modrusan; Lawren C Wu; Harold R Collard; Paul J Wolters; Jackson G Egen; Joseph R Arron
Journal:  J Immunol       Date:  2014-05-30       Impact factor: 5.422

Review 9.  Signaling mechanisms of the epithelial-mesenchymal transition.

Authors:  David M Gonzalez; Damian Medici
Journal:  Sci Signal       Date:  2014-09-23       Impact factor: 8.192

10.  IL-13 is a therapeutic target in radiation lung injury.

Authors:  Su I Chung; Jason A Horton; Thirumalai R Ramalingam; Ayla O White; Eun Joo Chung; Kathryn E Hudak; Bradley T Scroggins; Joseph R Arron; Thomas A Wynn; Deborah E Citrin
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

View more
  13 in total

1.  Fibrocyte accumulation in the lungs of cystic fibrosis patients.

Authors:  Rajesh K Kasam; Prathibha R Gajjala; Anil G Jegga; Jennifer A Courtney; Scott H Randell; Elizabeth L Kramer; John P Clancy; Satish K Madala
Journal:  J Cyst Fibros       Date:  2020-06-25       Impact factor: 5.482

2.  Fra-2-expressing macrophages promote lung fibrosis in mice.

Authors:  Alvaro C Ucero; Latifa Bakiri; Ben Roediger; Masakatsu Suzuki; Maria Jimenez; Pratyusha Mandal; Paola Braghetta; Paolo Bonaldo; Luis Paz-Ares; Coral Fustero-Torre; Pilar Ximenez-Embun; Ana Isabel Hernandez; Diego Megias; Erwin F Wagner
Journal:  J Clin Invest       Date:  2019-05-28       Impact factor: 14.808

Review 3.  New therapeutics based on emerging concepts in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Prathibha R Gajjala; Rajesh K Kasam; Satish K Madala
Journal:  Expert Opin Ther Targets       Date:  2018-11-28       Impact factor: 6.902

Review 4.  Fibrosis: from mechanisms to medicines.

Authors:  Neil C Henderson; Florian Rieder; Thomas A Wynn
Journal:  Nature       Date:  2020-11-25       Impact factor: 49.962

5.  Bronchoalveolar lavage cell profiles and proteins concentrations can be used to phenotype extrinsic allergic alveolitis patients.

Authors:  Martina Sterclova; Magdalena Smetakova; Ludek Stehlik; Jelena Skibova; Martina Vasakova
Journal:  Multidiscip Respir Med       Date:  2019-03-12

6.  Aberrant populations of circulating T follicular helper cells and regulatory B cells underlying idiopathic pulmonary fibrosis.

Authors:  Yuichiro Asai; Hirofumi Chiba; Hirotaka Nishikiori; Ryuta Kamekura; Hayato Yabe; Shun Kondo; Satsuki Miyajima; Katsunori Shigehara; Shingo Ichimiya; Hiroki Takahashi
Journal:  Respir Res       Date:  2019-11-06

7.  Non-Canonical Regulation of Type I Collagen through Promoter Binding of SOX2 and Its Contribution to Ameliorating Pulmonary Fibrosis by Butylidenephthalide.

Authors:  Hong-Meng Chuang; Li-Ing Ho; Mao-Hsuan Huang; Kun-Lun Huang; Tzyy-Wen Chiou; Shinn-Zong Lin; Hong-Lin Su; Horng-Jyh Harn
Journal:  Int J Mol Sci       Date:  2018-10-04       Impact factor: 5.923

Review 8.  Epithelial-stromal crosstalk and fibrosis in eosinophilic esophagitis.

Authors:  Amanda B Muir; Joshua X Wang; Hiroshi Nakagawa
Journal:  J Gastroenterol       Date:  2018-08-12       Impact factor: 6.772

9.  Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis.

Authors:  Rajesh K Kasam; Sudhir Ghandikota; Divyalakshmi Soundararajan; Geereddy B Reddy; Steven K Huang; Anil G Jegga; Satish K Madala
Journal:  EMBO Mol Med       Date:  2020-08-06       Impact factor: 12.137

Review 10.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.